abrdn Healthcare Investors Shares of Beneficial Interest (HQH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
No matching records found (checked Nov 16, 2026)
No matching records found (checked Nov 21, 2026)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 41/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 0 | No records No matching records found (checked Nov 16, 2026) |
ClinicalTrials.gov checked Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 21, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 21, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 21, 2026 |
| Publications | 0 | No records No matching records found (checked Nov 21, 2026) |
PubMed checked Nov 21, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 9.9/100 (grade F):
- Dilution risk: signal score 0.41, weight used 22%, 9.1 points
- Short interest: signal score 0.10, weight used 8%, 0.8 points
- Clinical trials: signal score 0.00, weight used 69%, 0.0 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for abrdn Healthcare Investors Shares of Beneficial Interest.
Full HQH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.